Trial Profile
A Double-blind, Randomized, Placebo-controlled, Four-way Crossover Phase 1 Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Effect of Repeated Daily Doses of 10 mg and 30 mg Macitentan on the QT/QTc Interval of the ECG in Healthy Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Bacterial infections; Eisenmenger complex; Glioblastoma; Infections; Pelvic inflammatory disorders; Pulmonary arterial hypertension; Skin ulcer
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 09 Feb 2014 New trial record